Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.
Rinaldi L, Messina V, Di Marco V, Iovinella V, Claar E, Cariti G, Sacco R, De Luca M, Scifo G, Gatti P, Barbarini G, Pace Palitti V, Quartini M, Tundo P, D'Offizi G, Parruti G, di Rosolini MA, Garrucciu G, Cosco L, Benanti F, Gimignani G, Vespasiani Gentilucci U, Di Lorenzo F, D'Antò M, Nevola R, Lupia T, Rosato V, Morbiducci V, Luzzitelli I, Sozio F, Di Stefano M, Ciraci E, Bulla F, Guarisco R, Cangiano C, Imparato M, Maggi P, Ascione A, Craxì A, Izzi A. Rinaldi L, et al. Among authors: de luca m. Am J Gastroenterol. 2021 Jun 1;116(6):1248-1255. doi: 10.14309/ajg.0000000000001147. Am J Gastroenterol. 2021. PMID: 34074828
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G. Ascione A, et al. Among authors: de luca m. Gastroenterology. 2010 Jan;138(1):116-22. doi: 10.1053/j.gastro.2009.10.005. Epub 2009 Oct 20. Gastroenterology. 2010. PMID: 19852964 Clinical Trial.
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
Rinaldi L, Perrella A, Guarino M, De Luca M, Piai G, Coppola N, Pafundi PC, Ciardiello F, Fasano M, Martinelli E, Valente G, Nevola R, Monari C, Miglioresi L, Guerrera B, Berretta M, Sasso FC, Morisco F, Izzi A, Adinolfi LE. Rinaldi L, et al. Among authors: de luca m. J Transl Med. 2019 Aug 28;17(1):292. doi: 10.1186/s12967-019-2033-x. J Transl Med. 2019. PMID: 31462268 Free PMC article.
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.
Cleo Study Group, Ascione A, Adinolfi LE, Amoroso P, Andriulli A, Armignacco O, Ascione T, Babudieri S, Barbarini G, Brogna M, Cesario F, Citro V, Claar E, Cozzolongo R, D'Adamo G, D'Amico E, Dattolo P, De Luca M, De Maria V, De Siena M, De Vita G, Di Giacomo A, De Marco R, De Stefano G, De Stefano G, Di Salvo S, Di Sarno R, Farella N, Felicioni L, Fimiani B, Fontanella L, Foti G, Furlan C, Giancotti F, Giolitto G, Gravina T, Guerrera B, Gulminetti R, Iacobellis A, Imparato M, Iodice A, Iovinella V, Izzi A, Liberti A, Leo P, Lettieri G, Luppino I, Marrone A, Mazzoni E, Messina V, Monarca R, Narciso V, Nosotti L, Pellicelli AM, Perrella A, Piai G, Picardi A, Pierri P, Pietromatera G, Resta F, Rinaldi L, Romano M, Rossini A, Russello M, Russo G, Sacco R, Sangiovanni V, Schiano A, Sciambra A, Scifo G, Simeone F, Sullo A, Tarquini P, Tundo P, Vallone A. Cleo Study Group, et al. Among authors: de siena m, de vita g, de marco r, de luca m, de maria v, de stefano g. World J Hepatol. 2016 Aug 8;8(22):949-56. doi: 10.4254/wjh.v8.i22.949. World J Hepatol. 2016. PMID: 27574549 Free PMC article.
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Ascione A, De Luca M, Melazzini M, Montilla S, Trotta MP, Petta S, Puoti M, Sangiovanni V, Messina V, Bruno S, Izzi A, Villa E, Aghemo A, Zignego AL, Orlandini A, Fontanella L, Gasbarrini A, Marzioni M, Giannini EG, Craxì A; ABACUS Study Group. Ascione A, et al. Among authors: de luca m. Infection. 2018 Oct;46(5):607-615. doi: 10.1007/s15010-018-1157-x. Epub 2018 May 28. Infection. 2018. PMID: 29808463
Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.
Ascione A, De Luca M, Di Costanzo GG, Picciotto FP, Lanza AG, Canestrini C, Morisco F, Tuccillo C, Caporaso N. Ascione A, et al. Among authors: de luca m. Curr Pharm Des. 2002;8(11):977-80. doi: 10.2174/1381612024607018. Curr Pharm Des. 2002. PMID: 11945144 Clinical Trial.
Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.
Ascione A, De Luca M, Canestrini C, Di Costanzo GG, Raimondo G, Longo G, Manns MP, Tillmann HL, Forte GB, Rocco P, Biceglia O, Faleo D, Vinelli F, Cela EM, Amitrano L, Addario L, Gigliotti T. Ascione A, et al. Among authors: de luca m. Ital J Gastroenterol Hepatol. 1998 Oct;30(5):517-23. Ital J Gastroenterol Hepatol. 1998. PMID: 9836109 Clinical Trial.
Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis.
Di Costanzo GG, De Luca M, Tritto G, Lampasi F, Addario L, Lanza AG, Tartaglione MT, Picciotto FP, Ascione A. Di Costanzo GG, et al. Among authors: de luca m. Eur J Gastroenterol Hepatol. 2008 Jul;20(7):674-9. doi: 10.1097/MEG.0b013e3282f762e1. Eur J Gastroenterol Hepatol. 2008. PMID: 18679071
1,217 results